Search / Trial NCT00001632

Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999

Trial Information

Current as of December 09, 2024

Completed

Keywords

Hypertrophy Integrated Backscatter Cyclic Echocardiography Hypertrophic Cardiomyopathy

ClinConnect Summary

Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease that is characterized by unexplained left ventricular hypertrophy (LVH) often associated with diastolic dysfunction and myocardial ischemia. In patients with HCM, LVH may be present at birth or it may develop during childhood and adolescence, usually during periods of rapid body growth. Currently, it is not possible to identify, using clinical or laboratory methods, those children who will develop LVH from among those with a genetic predisposition for the disease. It would therefore be beneficial to find predictors of LVH ...

Gender

ALL

Eligibility criteria

  • INCLUSION CRITERIA:
  • Three groups of subjects (aged 1-15 years) will be studied: normal children, children with HCM, and children that are family members of patients with HCM, but do not themselves have any evidence of LVH.
  • CONTROL GROUP (NORM GROUP):
  • Normal children under the age of 15 who have a normal two-dimensional echocardiogram will be included in the study.
  • HYPERTROPHIC CARDIOMYOPATHY GROUP (HCM GROUP):
  • Patients with HCM (unexplained LVH on two-dimensional echocardiogram) under the age of 15 will be included.
  • Family History of Hypertrophic Cardiomyopathy Group (FHCM GROUP:
  • Normal children under the age of 15 who have a first-degree relative with HCM and a normal two-dimensional echocardiogram will be included.
  • EXCLUSION CRITERIA - CONTROL GROUP:
  • Exclusion criteria will be any historical or echocardiographic evidence of congenital or valvular heart disease or any form of cardiomyopathy.
  • EXCLUSION CRITERIA - HCM GROUP:
  • Exclusion criteria will be any evidence of congenital or valvular heart disease that may explain the presence of LVH.
  • EXCLUSION CRITERIA - FHCM GROUP:
  • Exclusion criteria will be any historical or echocardiographic evidence of congenital or valvular heart disease or other form of cardiomyopathy.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials